When does the weight loss plateau occur on drugs like Ozempic, and can you delay it?

Health & Lifestyle
192

Listen to article (english)

Translate to Spanish or other 102 languages!

When is a person likely to reach a weight loss plateau on GLP-1 agonists vs surgery vs dietary interventions? Image for illustration purposes
When is a person likely to reach a weight loss plateau on GLP-1 agonists vs surgery vs dietary interventions? Image for illustration purposes

Medical News Today

- Advertisement -
  • A new study investigated why different obesity treatments, including diets, surgeries and new medications like GLP-1 receptor agonists, such as semaglutide and tirzepatide, lead to varying times at which weight loss plateaus.
  • Utilizing a mathematical model, the research examines how these interventions alter the body’s regulation of energy intake and expenditure, affecting the duration of effective weight loss.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/when-does-the-loss-plateau-occur-on-drugs-like-ozempic-and-can-you-delay-it

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Vaccines for Family & Caregivers 
Next article
Weight-Loss Surgery Before Kidney Transplantation Improves Health & Eligibility of Patients with Obesity & Renal Failure

More Articles

Study: Supplement Plus Chemo Boosts Pancreatic Cancer Survival

L-glutamine, an amino acid that occurs naturally in the body and plays an important role in digestion, has been studied as a potential way to ease side effects in other cancers.

How Artificial Intelligence Is Improving Prostate Cancer Diagnostics

Mega Doctor News CLEVELAND CLINIC - September is Prostate Cancer Awareness Month.  Prostate cancer is...

New Strategies to Soothe Dry Eyes

Anyone who has ever endured burning, itchy eyes or extra tearing knows that these symptoms are tough to ignore.

FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.
- Advertisement -